BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

226 related articles for article (PubMed ID: 27476806)

  • 1. Comparison of Injectable and Oral Antipsychotics in Relapse Rates in a Pragmatic 30-Month Schizophrenia Relapse Prevention Study.
    Buckley PF; Schooler NR; Goff DC; Kopelowicz A; Lauriello J; Manschreck TC; Mendelowitz A; Miller DD; Wilson DR; Ames D; Bustillo JR; Kane JM; Looney SW
    Psychiatr Serv; 2016 Dec; 67(12):1370-1372. PubMed ID: 27476806
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Comparison of SGA oral medications and a long-acting injectable SGA: the PROACTIVE study.
    Buckley PF; Schooler NR; Goff DC; Hsiao J; Kopelowicz A; Lauriello J; Manschreck T; Mendelowitz AJ; Miller del D; Severe JB; Wilson DR; Ames D; Bustillo J; Mintz J; Kane JM;
    Schizophr Bull; 2015 Mar; 41(2):449-59. PubMed ID: 24870446
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Oral versus injectable antipsychotic treatment in early psychosis: post hoc comparison of two studies.
    Emsley R; Oosthuizen P; Koen L; Niehaus DJ; Medori R; Rabinowitz J
    Clin Ther; 2008 Dec; 30(12):2378-86. PubMed ID: 19167596
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Long-Acting Injectable Risperidone for Relapse Prevention and Control of Breakthrough Symptoms After a Recent First Episode of Schizophrenia. A Randomized Clinical Trial.
    Subotnik KL; Casaus LR; Ventura J; Luo JS; Hellemann GS; Gretchen-Doorly D; Marder S; Nuechterlein KH
    JAMA Psychiatry; 2015 Aug; 72(8):822-9. PubMed ID: 26107752
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Combination Antipsychotic Therapies: An Analysis From a Longitudinal Pragmatic Trial.
    Foster A; Buckley P; Lauriello J; Looney S; Schooler N
    J Clin Psychopharmacol; 2017 Oct; 37(5):595-599. PubMed ID: 28806390
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Rationale for the use of long-acting injectable risperidone: a survey of French psychiatrists].
    Misdrahi D; Delgado A; Bouju S; Comet D; Chiariny JF
    Encephale; 2013 May; 39 Suppl 1():S8-14. PubMed ID: 23541914
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effectiveness of long-acting injectable risperidone versus oral antipsychotics in the treatment of recent-onset schizophrenia: a case-control study.
    Barrio P; Batalla A; Castellví P; Hidalgo D; García M; Ortiz A; Grande I; Pons A; Parellada E
    Int Clin Psychopharmacol; 2013 Jul; 28(4):164-70. PubMed ID: 23587986
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Antipsychotic formulation and one-year rehospitalization of schizophrenia patients: a population-based cohort study.
    Huang SS; Lin CH; Loh el-W; Yang HY; Chan CH; Lan TH
    Psychiatr Serv; 2013 Dec; 64(12):1259-62. PubMed ID: 24292730
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Switching stable patients with schizophrenia from depot and oral antipsychotics to long-acting injectable risperidone: reasons for switching and safety.
    Hawley C; Turner M; Latif MA; Curtis V; Saleem PT; Wilton K
    Hum Psychopharmacol; 2010 Jan; 25(1):37-46. PubMed ID: 20041474
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Predicting relapse with residual symptoms in schizophrenia: A secondary analysis of the PROACTIVE trial.
    Saito Y; Sakurai H; Kane JM; Schooler NR; Suzuki T; Mimura M; Uchida H
    Schizophr Res; 2020 Jan; 215():173-180. PubMed ID: 31672387
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Do Long-Acting Injectable Antipsychotics Prevent or Delay Hospital Readmission?
    Maestri TJ; Mican LM; Rozea H; Barner JC
    Psychopharmacol Bull; 2018 Mar; 48(3):8-15. PubMed ID: 29713100
    [TBL] [Abstract][Full Text] [Related]  

  • 12. An Exploratory, Open-Label, Randomized Trial Comparing Risperidone Long-Acting Injectable with Oral Antipsychotic Medication in the Treatment of Early Psychosis.
    Malla A; Chue P; Jordan G; Stip E; Koczerginski D; Milliken H; Joseph A; Williams R; Adams B; Manchanda R; Oyewumi K; Roy MA
    Clin Schizophr Relat Psychoses; 2016; 9(4):198-208. PubMed ID: 23773886
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [French Society for Biological Psychiatry and Neuropsychopharmacology task force: Formal Consensus for the prescription of depot antipsychotics].
    Samalin L; Abbar M; Courtet P; Guillaume S; Lancrenon S; Llorca PM
    Encephale; 2013 Dec; 39 Suppl 4():189-203. PubMed ID: 24373464
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Differences in treatment effect among clinical subgroups in a randomized clinical trial of long-acting injectable risperidone and oral antipsychotics in unstable chronic schizophrenia.
    Leatherman SM; Liang MH; Krystal JH; Lew RA; Valley D; Thwin SS; Rosenheck RA;
    J Nerv Ment Dis; 2014 Jan; 202(1):13-7. PubMed ID: 24375206
    [TBL] [Abstract][Full Text] [Related]  

  • 15. An assessment of emergent tardive dyskinesia and existing dyskinesia in patients receiving long-acting, injectable risperidone: results from a long-term study.
    Gharabawi GM; Bossie CA; Zhu Y; Mao L; Lasser RA
    Schizophr Res; 2005 Sep; 77(2-3):129-39. PubMed ID: 15913962
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Maintenance treatment with long-acting injectable risperidone in first-episode schizophrenia: a randomized effectiveness study.
    Weiden PJ; Schooler NR; Weedon JC; Elmouchtari A; Sunakawa-McMillan A
    J Clin Psychiatry; 2012 Sep; 73(9):1224-33. PubMed ID: 22938760
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Treatment of schizophrenia with depot preparations of fluphenazine, haloperidol, and risperidone among inpatients at state-operated psychiatric facilities.
    Citrome L; Jaffe A; Levine J
    Schizophr Res; 2010 Jun; 119(1-3):153-9. PubMed ID: 20347267
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Long-acting injectable risperidone v. olanzapine tablets for schizophrenia or schizoaffective disorder. Randomised, controlled, open-label study.
    Keks NA; Ingham M; Khan A; Karcher K
    Br J Psychiatry; 2007 Aug; 191():131-9. PubMed ID: 17666497
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Strategies for improving compliance in treatment of schizophrenia by using a long-acting formulation of an antipsychotic: clinical studies.
    Kane JM
    J Clin Psychiatry; 2003; 64 Suppl 16():34-40. PubMed ID: 14680417
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Review of treatments that can ameliorate nonadherence in patients with schizophrenia.
    Kane JM
    J Clin Psychiatry; 2006; 67 Suppl 5():9-14. PubMed ID: 16822091
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.